Durvalumab (anti-PD-L1)

製品コード：A2013        

印刷

Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.

製品説明

CAS No. 1428935-60-7
Formulation 100 mM Pro-Ac, 20 mM Arg, pH 5.0
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions

カスタマーフィードバック

A2013-Durvalumab-(anti-PD-L1).gif

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

PPP2R1A mutations portend improved survival after cancer immunotherapy [ Nature, 2025, 10.1038/s41586-025-09203-8] PubMed: 40604275
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC [ J Biomed Sci, 2025, 32(1):94] PubMed: 41068729
Macrophage-derived pro-inflammatory cytokines augment the cytotoxicity of cytokine-induced killer cells by strengthening the NKG2D pathway in multiple myeloma [ Sci Rep, 2025, 15(1):16739] PubMed: 40369131
Antigenic cancer persister cells survive direct T cell attack [ bioRxiv, 2025, 2025.03.14.643359] PubMed: 40166148
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia [ Pharmacol Res, 2024, 199:107048] PubMed: 38145833
Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker [ J Biol Chem, 2024, S0021-9258(24)01826-X] PubMed: 38685532
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab [ Am J Nucl Med Mol Imaging, 2024, 14(1):31-40] PubMed: 38500749
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab [ Am J Nucl Med Mol Imaging, 2024, 14(1):31-40] PubMed: 38500749
Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer [ Heliyon, 2023, 9(6):e15782] PubMed: 37389074
Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune [ Heliyon, 2023, 9(6):e15782.] PubMed: 37389074

人間や獣医の診断であるか治療的な使用のためにでない。